France· FR:68879708
ESKAZOLE 400 mg, comprimé
A albendazole product containing albendazole, registered in France by GLAXOSMITHKLINE, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Albendazole is registered in 10 of 19 countries.
Countries holding a registration under ATC P02CA03 (albendazole), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 6 of them publish a price we can compare per daily dose
Albendazole · ATC P02CA03
10 / 19 countries
- Czechiaprice
- Franceprice
- Germany
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of albendazole costs, country by country.
Normalised to the WHO defined daily dose (0.8 g), the median price runs from $5.63 in France to $36.54 in Switzerland — a ×6.5 gap.
- France: $5.63 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Albendazole · price per daily dose (0.8 g)
USD · FX 28 Sept 2026
- CH Switzerland$36.54
- FR France$5.63
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ALBENDAZOLE
- Manufacturer
- GLAXOSMITHKLINE
- Country
- France (FR)
- ATC code
- P02CA03
- ATC class
- Albendazole
- Defined daily dose
- 0.8 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
1 priced- cip133400936866829plaquette(s) PVC PVDC aluminium de 56 comprimé(s)
- cip133400936867420flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 60 comprimé(s)EUR 129.82
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
114 interactions on record for albendazole.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Albendazole · interactions on record
114 records
- 3 severe
- 102 moderate
- 9 minor
Most severe, free to view
- CladribineL01BB04severe
- CladribineL04AA40severe
- ClozapineN05AH02severe
- AprepitantA04AD12moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Albendazole in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAlbendazole 400mg tabletsPart VIIID Drug Tariff Special Order
- NorwayEskazoleGlaxoSmithKline
- SpainESKAZOLE 400 MG COMPRIMIDOSGlaxosmithkline S.A.
- NetherlandsEskazole 400 mg, tablettenEuro Registratie Collectief B.V.
- PolandZentelPretium Farm Sp. z o.o.
- United StatesAlbendazoleAlembic Pharmaceuticals Limited
- SwitzerlandZentel, KautablettenGlaxoSmithKline AG
- GermanyAlbendazol Micro LabsMicro Labs Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 16 EEA countries. Names it is sold under:
- Austria · Eskazole
- Bulgaria · Зентел
- Cyprus · Zestaval
- Germany · Albendazol Micro Labs, Eskazole
- Spain · Eskazole
- United Kingdom (Northern Ireland) · Albendazole Brown & Burk Uk
- Greece · Albendol
- Hungary · Albendazol Pharma Vim
- Italy · Zentel
- Luxembourg · Albendazol Micro Labs
- Malta · Zestaval
- Netherlands · Eskazole
- Poland · Zentel
- Portugal · Zentel
- Romania · Albendazol Vim Spectrum, Duador
- Slovakia · Zentel
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3ee6bbc8-40c2-4914-845c-a56b9df42e0b GET /v1/drugs/3ee6bbc8-40c2-4914-845c-a56b9df42e0b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68879708",
"date_amm": "2005-05-24",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "ALBENDAZOLE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about albendazole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.